Supplemental material, sj-docx-1-opp-10.1177_10781552231203723 for Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration by Xiangjian Wang, Tao Fu and Weilian Sun in Journal of Oncology Pharmacy Practice</p
Supplemental material, sj-docx-1-tam-10.1177_17588359231220516 for TQB2450 in patients with advanced...
Supplemental material, sj-docx-1-onc-10.1177_11795549231218082 for A Phase II Study of 131I-rituxima...
Supplemental material, sj-docx-1-opp-10.1177_10781552221148118 for VicTAG chemotherapy audit toolkit...
Supplemental material, sj-docx-1-opp-10.1177_10781552221150936 for Recurrent and atypical immune che...
Supplemental material, sj-docx-1-opp-10.1177_10781552231189192 for Pure red cell aplasia occurring d...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203703 for Cabozantinib-induced heart failur...
Supplemental material, sj-docx-1-tam-10.1177_17588359231204854 for Modulation of gut microbiota: a n...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203186 for Polysorbate 80 as a possible alle...
Supplemental material, sj-docx-1-tam-10.1177_17588359221148541 for Atezolizumab plus bevacizumab in ...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-5-ajr-10.1177_19458924221132065 for Circulating T Cell Subsets and IL...
Supplemental material, sj-docx-1-tam-10.1177_17588359231220509 for Short-term outcomes of combined t...
Supplemental material, sj-docx-1-cms-10.1177_12034754231220929 for GLP-1R Agonists in Psoriasis Pati...
Supplemental material, sj-docx-1-npx-10.1177_1934578X221126964 for A Study on the Mechanism of Herba...
Supplemental material, sj-docx-1-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-1-tam-10.1177_17588359231220516 for TQB2450 in patients with advanced...
Supplemental material, sj-docx-1-onc-10.1177_11795549231218082 for A Phase II Study of 131I-rituxima...
Supplemental material, sj-docx-1-opp-10.1177_10781552221148118 for VicTAG chemotherapy audit toolkit...
Supplemental material, sj-docx-1-opp-10.1177_10781552221150936 for Recurrent and atypical immune che...
Supplemental material, sj-docx-1-opp-10.1177_10781552231189192 for Pure red cell aplasia occurring d...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203703 for Cabozantinib-induced heart failur...
Supplemental material, sj-docx-1-tam-10.1177_17588359231204854 for Modulation of gut microbiota: a n...
Supplemental material, sj-docx-1-opp-10.1177_10781552231203186 for Polysorbate 80 as a possible alle...
Supplemental material, sj-docx-1-tam-10.1177_17588359221148541 for Atezolizumab plus bevacizumab in ...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-5-ajr-10.1177_19458924221132065 for Circulating T Cell Subsets and IL...
Supplemental material, sj-docx-1-tam-10.1177_17588359231220509 for Short-term outcomes of combined t...
Supplemental material, sj-docx-1-cms-10.1177_12034754231220929 for GLP-1R Agonists in Psoriasis Pati...
Supplemental material, sj-docx-1-npx-10.1177_1934578X221126964 for A Study on the Mechanism of Herba...
Supplemental material, sj-docx-1-opp-10.1177_10781552221126102 for Transition to ePrescribing for sy...
Supplemental material, sj-docx-1-tam-10.1177_17588359231220516 for TQB2450 in patients with advanced...
Supplemental material, sj-docx-1-onc-10.1177_11795549231218082 for A Phase II Study of 131I-rituxima...
Supplemental material, sj-docx-1-opp-10.1177_10781552221148118 for VicTAG chemotherapy audit toolkit...